Adipose tissue-derived Mesenchymal Stromal Cells
Phase 1Small molecule
Adipose tissue-derived Mesenchymal Stromal Cells is one of 18 small molecule programs targeting Primary Progressive Multiple Sclerosis. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
17
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
19 competitors in Primary Progressive Multiple Sclerosis
#DrugCompanyPhaseTrials
1Gilenya
NovartisApproved
Ocrevus
RochePhase 3
Glucophage
EMD SeronoApproved
Medrol
PfizerPhase 3
Droxia
TTheravia
Phase 3
Nublexa
BBeijing InnoCare Pharma Tech Co., Ltd.
Phase 3
Tecfidera
BiogenPhase 2
Plaquenil
Alnylam PharmaceuticalsPhase 2
Antihistamine
Arrowhead PharmaceuticalsPhase 3
Fenebrutinib
RochePhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- RRennes University Hospital